Biomarker Study of Pancreatic Neuroendocrine Tumours

Uppsala University

Status: Enrolling

Conditions: Pancreatic Neuroendocrine Tumor

Treatments: Radiation: 18F-FDG-PET; Other: Core needle biopsy; Radiation: Computed tomography; Radiation: 68Ga-DOTATOC-PET; Other: Phlebotomy

Study type: Observational

Funder types: Other

Identifiers

NCT03741517

PRORESS pancreas

Details and patient eligibility

About

The biology of pancreatic neuroendocrine tumors can change during the disease course. This evolution of disease can manifest through increases in tumor proliferation rate, resistance to medical therapy and/or a change in tumor hormone secretion. This study aims to characterize how the biology of pancreatic neuroendocrine tumors change over time, measured by; patient symptoms, biochemistry, contrast enhanced computed tomography, DOTATOC-PET, FDG-PET and core needle biopsy with histopathological analysis (Ki67 index and tumor cell differentiation). Uptake on 68Ga-DOTATOC and 18F-FDG-PET will be correlated directly to tumor cell proliferation rate. Fraction of patients with spatial heterogeneity in DOTATOC as well as FDG uptake as well as metachronous changes in all collected data will be documented. Biomaterial from whole blood and core needle biopsies will be characterized on the molecular level, and those findings will be integrated to the above specified clinical parameters.

Enrollment: 40 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥18 years
• Informed consent
• Pathology confirmed diagnosis of pancreatic neuroendocrine tumor WHO grade 1-3 or neuroendocrine carcinoma grade 3.

Exclusion criteria

• Patient does not consent
• Pregnancy or no contraceptive in fertile women.